Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conflicts of interest br Introduction Photodynamic Therap
2024-05-14

Conflicts of interest Introduction Photodynamic Therapy (PDT) is a technique used for the treatment of several malignant and non malignant diseases (Akimoto, 2016, Keyal, Bhatta, Wang, 2016, Morton, Szeimies, Sidoroff, Wennberg, Basset-Seguin, Calzavara-Pinton, Gilaberte, Hofbauer, Hunger, Kar
-
br Physiology of the apelin
2024-05-14

Physiology of the apelin pathway Role of apelin in heart disease Both apelin and apelin receptor null mice manifested moderate reduction in cardiac contractile function under basal conditions and their exercise capacity was markedly reduced (Table 1) [56]. Apelin has direct effects on the prop
-
br Conflict of interest br Acknowledgement We wish
2024-05-13

Conflict of interest Acknowledgement We wish to thank the Program of National Key R&D Program of China (2017YFD0200500) and the Fundamental Research Funds for the Central Universities (KYTZ201604) for partially funding this work. Introduction Chitosan ((1→4)-2-amino-2-deoxy-β-d-glucose) is
-
Here we found that AMPK directly
2024-05-13

Here we found that AMPK directly phosphorylates EZH2 at Thr311 to disrupt its interaction with SUZ12 and to inhibit PRC2 enzymatic activity, which is supported by the increased expression of PRC2-repressed genes. Furthermore, the T311E-EZH2 mutant that mimics AMPK-mediated phosphorylation status sup
-
Since all the above vascular and glomerular effects contribu
2024-05-13

Since all the above vascular and glomerular effects contribute to blood pressure regulation, it is expected for 12/15-LOX pathway to play a role in pathogenesis of hypertension (Fig. 6). Indeed, there is evidence for alterations of the 12- and 15LOX enzymes and metabolites both in humans with essent
-
A rate limiting step in the generation of kynurenine and
2024-05-13

A rate-limiting step in the generation of kynurenine and xanthurenic akt pathway is the oxidation of N-formyl-kynurenine to l-kynurenine via indolamine 2,3-dioxygenase (IDO) or tryptophan dioxygenase (TDO). IDO and/or TDO knockdown decreases and ectopic over-expression increases production of endog
-
br Conflict of interest br
2024-05-13

Conflict of interest Ethics committee Introduction Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is characterized by impaired function and differentiation of T, B, and natural killer (NK) cells. Non-immunological abnormalities may also occur, including fa
-
br Materials and methods br Results br Discussion Prostate
2024-05-13

Materials and methods Results Discussion Prostate cancer represents an ideal candidate for chemoprevention because of its high incidence and long latency to clinically significant disease [17]. The precancerous lesion PIN may also be a suitable target for ablation in chemoprevention strateg
-
br Experimental procedure br Introduction
2024-05-13

Experimental procedure Introduction Migraine is a debilitating neurovascular disorder characterized by recurring unilateral pulsating headaches of moderate to severe intensity, associated with nausea, photophobia and/or phonophobia, lasting from 4 to 72 h (Headache Classification Committee of
-
CGS 21680 In this scenario the receptor tyrosine kinase inhi
2024-05-13

In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; PCGS 21680 in
-
Currently NSAIDs which achieve antineoplastic actions mainly
2024-05-11

Currently, NSAIDs which achieve antineoplastic actions mainly through apoptosis are emerging choice in chemotherapy. Their antineoplastic effects were demonstrated before in tumor-bearing models [5], [6], [7]. Through in vitro cell models, we identified an indomethacin-activation of ceramide/PP2A/Ak
-
These experiments make it clear that one can study the
2024-05-11

These experiments make it clear that one can study the effect of antimalaria drugs that target the DHFR enzyme of P. falciparum by transferring the malaria enzyme into S. cerevisiae. The ease of growth and manipulation of the yeast make it easy to measure the sensitivity of any particular dhfr allel
-
br Results br Discussion Evaluation
2024-05-11

Results Discussion Evaluation of antimicrobial usage is standardized using the DDD as a recommended strategy for comparison with similar hospitals [13]. The use of risk adjustment is needed to overcome the challenge of benchmarking. Two patient characteristics are associated with clinical outc
-
Regarding progression free survival analyzing
2024-05-11

Regarding progression free-survival, analyzing 12 clinical trials, we demonstrated that the use of antiangiogenic treatment results in a statistically longer PFS with a pooled HR of 0.76 (95% CI 0.65–0.89, pZ-DEVD-FMK of improvement of PFS only is that after antiangiogenic therapy glioblastomas app
-
br Implementation of sacubitril valsartan into clinical prac
2024-05-11

Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio
16080 records 156/1072 page Previous Next First page 上5页 156157158159160 下5页 Last page